Raw Data summary for the manuscript "Towards Human Cardiac New Approach Methodologies (NAMs) to Evaluate the Combination of Repolarization Prolonging and Shortening Drugs a pilot study"

This study evaluated the cardiac safety of combining moxifloxacin (a QT-prolonging antibiotic) with cobicistat (a pharmacokinetic booster) using hiPSC-CMs cultured for 7-8 days. Results showed that cobicistat attenuated moxifloxacin-induced field potential duration prolongation and eliminated early afterdepolarizations at clinically relevant concentrations, reducing the Torsades de Pointes risk from high/intermediate to low. This work demonstrates the utility of in vitro cardiac NAMs for evaluating drug combination safety to support regulatory decision-making while reducing animal study dependence.